Avadel Pharmaceuticals plc (AVDL)
NASDAQ: AVDL · Real-Time Price · USD
21.34
-0.02 (-0.09%)
At close: Dec 5, 2025, 4:00 PM EST
21.52
+0.18 (0.84%)
After-hours: Dec 5, 2025, 7:30 PM EST
Avadel Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 8 professional analysts, the 12-month price target for Avadel Pharmaceuticals stock ranges from a low of $12 to a high of $22.5. The average analyst price target of $18.38 forecasts a -13.87% decrease in the stock price over the next year.
Price Target: $18.38 (-13.87%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Avadel Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 0 | 0 | 1 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 10 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $20 → $23 | Hold | Maintains | $20 → $23 | +5.44% | Nov 20, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $16 → $20 | Hold | Maintains | $16 → $20 | -6.28% | Nov 7, 2025 |
| UBS | UBS | Strong Buy → Hold Downgrades $20 | Strong Buy → Hold | Downgrades | $20 | -6.28% | Oct 28, 2025 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $19 | Buy → Hold | Downgrades | $19 | -13.31% | Oct 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $36 → $20 | Strong Buy → Hold | Downgrades | $36 → $20 | -6.28% | Oct 23, 2025 |
Financial Forecast
Revenue This Year
279.84M
from 169.12M
Increased by 65.47%
Revenue Next Year
366.25M
from 279.84M
Increased by 30.88%
EPS This Year
0.20
from -0.51
EPS Next Year
0.83
from 0.20
Increased by 313.31%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 295.2M | 397.2M | ||||
| Avg | 279.8M | 366.3M | ||||
| Low | 261.7M | 338.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 74.5% | 41.9% | ||||
| Avg | 65.5% | 30.9% | ||||
| Low | 54.7% | 20.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.36 | 1.20 | ||||
| Avg | 0.20 | 0.83 | ||||
| Low | 0.11 | 0.57 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 499.6% | ||||
| Avg | - | 313.3% | ||||
| Low | - | 184.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.